Ubrelvy Tablet
Product Images NDC 0023-6501

5 FDA label images from Allergan, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Ubrelvy (NDC 0023-6501). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

The Following Structural Formula For Ubrelvy Is Ubrogepant, A Calcitonin Gene-related Peptide (cgrp) Receptor Antagonist. The Chemical Name Of Ubrogepant Is (3's)-n-((3s,5s,6r)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide. (Ubrelvy 01)

The Following Structural Formula For Ubrelvy Is Ubrogepant, A Calcitonin Gene-related Peptide (cgrp) Receptor Antagonist. The Chemical Name Of Ubrogepant Is (3's)-n-((3s,5s,6r)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide. (Ubrelvy 01)
Chemical structure diagram of ubrogepant, the active ingredient in UBRELVY tablets. The diagram displays atom and bond connectivity characteristic of the molecular formula without additional annotations.*
FDA Label Image

Figure 1: Percentage Of Patients Achieving Pain Freedom Within 2 Hours In Pooled Studies 1 And 2 (Ubrelvy 02)

Figure 1: Percentage Of Patients Achieving Pain Freedom Within 2 Hours In Pooled Studies 1 And 2 (Ubrelvy 02)
A line graph illustrating the percent of patients achieving pain freedom over time up to 2 hours after dosing with UBRELVY tablets at 50 mg and 100 mg strengths compared to placebo. The x-axis represents time in hours from dose, and the y-axis shows the percentage achieving pain freedom, with both doses generally showing higher percentages than placebo over time.*
FDA Label Image

Figure 2: Percentage Of Patients Achieving Mbs Freedom Within 2 Hours In Pooled Studies 1 And 2 (Ubrelvy 03)

Figure 2: Percentage Of Patients Achieving Mbs Freedom Within 2 Hours In Pooled Studies 1 And 2 (Ubrelvy 03)
A line graph showing the percent of subjects achieving MBS freedom over time from dose. The x-axis represents time in hours (0 to 2 hours), and the y-axis shows percent achieving freedom (0% to 100%). Three lines compare UBRELVY 100 mg, UBRELVY 50 mg, and placebo, with UBRELVY doses showing higher percentages than placebo over time.*
FDA Label Image

Principal Display Panelndc 0023-6498-10contains 10 Tabletsrx Onlyubrelvy®(ubrogepant) Tablets50 mg (Ubrelvy 04)

Principal Display Panelndc 0023-6498-10contains 10 Tabletsrx Onlyubrelvy®(ubrogepant) Tablets50 mg (Ubrelvy 04)
UBRELVY 50 mg (ubrogepant) tablets carton label showing the product name, strength, and dosage form. The label indicates it is a prescription drug containing 10 tablets, with storage instructions and manufacturer information for Allergan, Inc.*
FDA Label Image

Principal Display Panelndc 0023-6501-10contains10 Tabletsrx Onlyubrelvy®(ubrogepant) Tablets100 mg (Ubrelvy 05)

Principal Display Panelndc 0023-6501-10contains10 Tabletsrx Onlyubrelvy®(ubrogepant) Tablets100 mg (Ubrelvy 05)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.